Posted at 11 Dec, 00:00h in News by alic 0 Comments GenEdit and Editas Medicine Enter into Exclusive License and Collaboration Agreement for Nanoparticle Gene Therapy Delivery | Business Wire GenEdit and Editas announce a worldwide, exclusive license and collaboration to enable safer and more effective delivery of CRISPR-based therapeutics. Tags: GenEdit ShareGenEdit and Editas Medicine Enter into Exclusive License and Collaboration Agreement for Nanoparticle Gene Therapy Delivery | Business Wire&media=', 'popupwindow', 'scrollbars=yes,width=800,height=400');popUp.focus();return false"> Print page 0 Likes
Sorry, the comment form is closed at this time.